Operator: The next question comes from Kristen Stewart with CL King.
Kristen Stewart: Congrats on a good quarter. I was wondering if you could just go into a little bit more detail on the new external trialing system. And sorry if I missed this but any thoughts on timing for that?
Raymond Cohen: So, yes, in terms of timing, we’re working diligently to be able to get that filed with the FDA in mid-2024. And assuming standard statutory timeline of the product, hopefully, we’ll be in the market by the end of next year. So it does take some time, as you can imagine. The product is now fully developed. But we’ve got to do all the validation, verification testing and that’s required and making the filing. So this is — the product is designed to eliminate a lot of the cables and things that are being used today, make it much more streamlined, lower profile. And most importantly, we’ve said this publicly before, the ability for patients to be able to take a shower when they’re undergoing that 3-day, typically 3-day, external trial.
So I could tell you there’s an enormous amount of enthusiasm amongst our customer base who have heard about the new product. And I think the combination of the foramen finder and the new external trial system, I mean, these things in combination should really help. And I think, Kristen, the piece of the puzzle here or the message that we’re really trying to get out to not only the investing public and our shareholders but also to our customers that Axonics is the innovator in this space. We’re the ones that are driving the market forward, coming up with new things and trying to make things more streamlined, et cetera, et cetera. And the message that we say to our customers and I’d say to shareholders, if you’re going to bet, bet on Axonics, because we’re not stopping.
And we’re listening very intently to feedback from our customers and we’re nimble enough to be able to react. And when we talk about one of our key values being thoughtful innovation, that’s really where it comes from, right, is listening, asking questions, listening and then taking it under advisement and making the changes. So I think that sacral neuromodulation has undergone a renaissance in our hands. And we will continue to push the envelope forward in terms of making this as easy as possible for caregivers and patients to get the symptom relief that they’re looking for. So I appreciate the question. I draw you a picture but it’s difficult to do live over the phone line but we’ll be having a lot more information about this in the coming year.
Operator: The next question comes from Shagun Singh with RBC Capital Markets.
Shagun Singh: I’m so sorry, I dropped. But, Ray, congratulations on a on a strong quarter and it does look like you have a lot of momentum going into ’24. I was just wondering if you can maybe talk to us about how you think about adjacencies or call points that Axonics could potentially expand into even though there is a lot of runway right now with your current businesses but you’ve add Bulkamid, that’s turned out really well. Just how do you think of IDNs, does that make sense, urology, women’s health? How do you think about it more broadly? And then separately, just how do you think about Axonics strategically? Would you be open to interest from other players?
Raymond Cohen: If I decode the last part of your message, I think you’re asking me, would Axonics be open to being acquired by a larger company. I think that’s the question. Is that how you heard it, Neil? Okay. So my answer to that would be Axonics’ stock is for sale every minute of every day and people — we encourage people to buy it. So you can buy a little bit, a lot of bit or the whole bit. And I think that that would be my reaction to that question. I mean none of us are here for lifetime employment. We’re here to create shareholder value, that’s the game. And so we’re certainly open. It’s not something we think about. We just focus on the execution of our business. The other question you asked is really — it’s really a big question and difficult to kind of get one’s arms around it.
